← Back to Clinical Trials
Recruiting NCT07238192

NCT07238192 Augmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07238192
Status Recruiting
Phase
Sponsor Ohio State University
Condition Posttraumatic Stress Disorder (PTSD)
Study Type INTERVENTIONAL
Enrollment 190 participants
Start Date 2026-01-28
Primary Completion 2027-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cognitive Processing Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 190 participants in total. It began in 2026-01-28 with a primary completion date of 2027-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research is to see if Crisis Response Planning (CRP), a brief strategy designed to help people cope effectively with emotional crises, combined with Cognitive Processing Therapy (CPT), a talk treatment for posttraumatic stress disorder (PTSD), will reduce suicidal thoughts and behaviors.

Eligibility Criteria

Inclusion Criteria: 1. Active duty service member or veteran aged 18 or older eligible for military medical care. 2. Able to read, write, and speak English. 3. Meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria within the past month) on the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). 4. Active suicidal ideation within the past week as assessed by scoring ≥ 1 on Scale for Suicidal Ideation (SSI) item 4 (i.e., active suicidal ideation within the past month) or report an interrupted, aborted, or actual suicide attempt within the preceding month on the Self-Injurious Thoughts and Behaviors Interview-Revised (SITBI-R). 5. Regular use of an iPhone or Android smartphone. Exclusion Criteria: 1. Inability to comprehend and complete the consent and baseline screening questionnaires. 2. Current suicide or homicide risk meriting crisis intervention. 3. Serious mental health symptoms, such as mania, psychosis, alcohol or substance use disorders warranting immediate clinical attention based on interviewer assessment and clinical judgement. 4. Currently engaged in evidence-based psychotherapy for PTSD (e.g., Cognitive Processing Therapy, Prolonged Exposure Therapy, Written Exposure Therapy).

Contact & Investigator

Central Contact

C. Rosie Bauder, PhD, MPH

✉ rosie.bauder@osumc.edu

📞 614-814-0119

Principal Investigator

Craig J Bryan

PRINCIPAL INVESTIGATOR

University of Vermont

Frequently Asked Questions

Who can join the NCT07238192 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Posttraumatic Stress Disorder (PTSD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07238192 currently recruiting?

Yes, NCT07238192 is actively recruiting participants. Contact the research team at rosie.bauder@osumc.edu for enrollment information.

Where is the NCT07238192 trial being conducted?

This trial is being conducted at Fort Hood, United States.

Who is sponsoring the NCT07238192 clinical trial?

NCT07238192 is sponsored by Ohio State University. The principal investigator is Craig J Bryan at University of Vermont. The trial plans to enroll 190 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology